Latest market price
5.92
+0.18+3.14%
OverviewShort InterestFilings
PHATQT28Phathom Pharmaceuticals, Inc.·NASDAQ
5.92+3.14%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-1.03Insider Own32.16%Shs Outstand80.90MPerf Week-0.34%
Market Cap478.93MForward P/E9.00EPS next Y0.66Insider Trans0.00%Shs Float65.39MPerf Month-14.45%
Enterprise Value298.93MPEG—EPS next Q—Short Float14.96%Perf Quarter-29.94%
Income-83.00MP/S1.74EPS this Y—Short Ratio6.98Perf Half Y-54.00%
Sales275.00MP/B—EPS next Y—ROA-24.06%Short Interest9.78MPerf YTD-64.32%
Book/sh-4.30P/C2.59EPS next 5Y—ROE—52W High18.31 -67.67%Perf Year-55.52%
Cash/sh2.29P/FCF—EPS past 3/5Y—ROIC-14.85%52W Low5.01 18.16%Perf 3Y-30.52%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin80.68%Volatility11.14% 7.90%Perf 5Y-80.55%
Dividend TTM—EV/Sales1.09EPS Y/Y TTM—Oper. Margin-9.26%ATR (14)0.57Perf 10Y—
Dividend Ex-Date—Quick Ratio1.72Sales Y/Y TTM84.56%Profit Margin-30.19%RSI (14)36.75Recom2.11
Dividend Gr. 3/5Y—Current Ratio1.76EPS Q/Q73.42%SMA20-11.71%Beta0.59Target Price16.50
Payout0.00%Debt/Eq—Sales Q/Q70.00%SMA50-21.92%Rel Volume1.95Prev Close5.74
Employees371LT Debt/Eq—EarningsFeb 25SMA200-43.06%Avg Volume1.44MPrice5.92
IPO DateOct 25, 2019Option/ShortYes / YesEPS/Sales Surpr.-19.60% 1.42%Net Debt/EBITDA—Volume2,812,512Change3.14%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-21-26ReiteratedCraig-HallumBuy$20 → $15
Oct-14-26ReiteratedJefferiesBuy$16
Sep-09-26InitiatedLeerinkMarket Perform$10
Jul-31-26ReiteratedCraig-HallumBuy$22 → $20
Jul-31-26ReiteratedGuggenheimBuy$20 → $22
Jul-30-26ReiteratedNeedhamBuy$26 → $22
Mar-27-26UpgradeBarclaysEqual Weight → Overweight$16 → $18
Feb-26-26ReiteratedStifel Nicolaus$24 → $28
Dec-11-25InitiatedRaymond JamesStrong Buy$28
Dec-08-25InitiatedBarclaysEqual Weight$16
Latest News· Times ET
Oct-29-26
Oct-29-2605:15PM
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Callmarketbeat.com
05:01PM
Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call SummaryYahoo
01:38PM
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcriptseekingalpha.com
09:36AM
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimateszacks.com
07:00AM
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com
Oct-26-26
Oct-26-2604:00AM
Phathom Pharmaceuticals Provides Update on FDA Litigationglobenewswire.com
Oct-23-26
Oct-23-2604:00AM
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAYahoo
Oct-19-26
Oct-19-2608:00AM
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026globenewswire.com
Oct-12-26
Oct-12-2604:03AM
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;Benzinga
Oct-08-26
Oct-08-2608:00AM
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meetingglobenewswire.com
Sep-29-26
Sep-29-2608:00AM
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERDglobenewswire.com
04:05AM
Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERDBenzinga
Sep-17-26
Sep-17-2603:41AM
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?defenseworld.net
Sep-16-26
Sep-16-2608:00PM
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Lawgurufocus.com
Sep-09-26
Sep-09-2608:13AM
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull CaseSeekingAlpha
Company

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue275175551—————
Cost of Goods Sold Incl. D&A532380—————
Gross Profit221153471—————
Selling, General and Administrative Excl. Other215280291118—————
Research and Development32333450—————
Other Operating Expense0-100—————
Operating Income-25-160-277-167—————
Interest Expense32687242—————
Unusual Expense
—————————
Non-Operating Income (Expense)-267158—————
Net Income Before Taxes-83-221-334-202—————
Income Taxes
0000—————
Consolidated Net Income-83-221-334-202—————
Net Income From Continuing Operations-83-221-334-202—————
Net Income-83-221-334-202—————
EPS (Recurring)-1.03-3.03-5.29-3.93—————
EPS (Basic, Before Extraordinaries)-1.03-3.03-5.29-3.93—————
EPS (Diluted)-1.03-3.03-5.29-3.93—————
EBITDA-21-152-262-159—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio1.836.929.30465.63—————
Gross Margin80.3687.4385.45100.00—————
Operating Margin-9.09-91.43-503.64-16,700.00—————
Net Margin-30.18-126.29-607.27-20,200.00—————
Shares Outstanding85736351—————
Market Capitalization5031,211512466—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$19.93$15.92$11.91$7.90$3.89● Close Price0.00K1.77K3.54K5.31K7.08KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Parikh AsitDirectorMay 20 '26Option Exercise4.9517,50086,62552,122May 21
Parikh AsitDirectorJan 13 '26Option Exercise10.308,75090,125131,000Jan 15
Parikh AsitDirectorDec 19 '25Option Exercise10.308,75090,125122,250Dec 23
Basta Steven LPresident and CEONov 28 '25Option Exercise0.0090,0000131,625Dec 02
Breedlove Robert CharlesPrincipal Accounting OfficerNov 03 '25Sale13.515247,07947,407Nov 05
Basta Steven LPresident and CEOSep 25 '25Option Exercise0.0090,000090,000Sep 26
Breedlove Robert CharlesPrincipal Accounting OfficerSep 05 '25Sale12.094615,57347,931Sep 09
Breedlove Robert CharlesPrincipal Accounting OfficerJul 16 '25Sale8.361,69214,15248,392Jul 18
Topper James NDirectorMay 21 '25Buy3.863,78014,60959,403May 23
Topper James NDirectorMay 14 '25Buy3.326,30020,91955,623May 15
Topper James NDirectorMay 13 '25Buy3.161,1203,54349,323May 15
Topper James NDirectorMay 12 '25Buy3.0412,60138,30148,203May 13
Topper James NDirectorMay 09 '25Buy3.2235,602114,61635,602May 13
Parikh AsitDirectorMay 07 '25Buy2.405,00011,98595,500May 08
Parikh AsitDirectorMay 06 '25Buy2.605,00013,00090,500May 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.